Mast cell inhibitor R112 is well tolerated and affects prostaglandin D₂ but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis

Authors: Guyer, Brenda J.; Shimamoto, S. Reed; Bradhurst, Amanda L.; Grossbard, Elliot B.; Dreskin, Stephen C.; Nelson, Harold S.

Source: Allergy and Asthma Proceedings, Volume 27, Number 3, May-June 2006 , pp. 208-213(6)

Publisher: OceanSide Publications, Inc

Buy & download fulltext article:

Price: $39.50 plus tax (Refund Policy)

Abstract:

Understanding of the role played by mast cells in allergic rhinitis (AR) has led to the development of novel therapies. The aim of this study was to determine the safety and tolerability of R112, an inhibitor of the tyrosine kinase Syk, in an allergen challenge model of AR. We also examined the effects of R112 on symptoms, mediator release, and nasal airway volumes. This double-blinded, randomized, placebo-controlled, crossover trial enrolled 20 out-of-season volunteers with AR. One intranasal dose of R112 or vehicle was administered and followed by an allergen challenge. In addition to safety monitoring, symptoms; changes in histamine, tryptase, and prostaglandin D₂ (PGD₂) content of nasal secretions; and acoustic rhinometry were determined over a 15-minute period. R112 was well tolerated. Adverse events were similar between treatments. Five minutes after allergen instillation, PGD₂ was decreased when subjects received R112 compared with vehicle (93.4 ± 23.0 pg/mL versus 171.6 ± 23.0 pg/mL; p = 0.03), and this correlated with rhinorrhea (p = 0.05). However, at 10 minutes, changes in PGD₂, tryptase, and histamine were not significant (46.8 ± 9.2 pg/mL versus 68.6 ± 9.2 pg/mL, p = 0.1; 9.5 ± 2.7 ng/mL versus 16.6 ± 2.9 ng/mL, p = 0.09; and 1.5 ± 1.6 ng/mL versus 3.5 ± 1.6 ng/mL, p = 0.4). No differences were found in symptoms or in acoustic rhinometry between treatment groups. Single-dose R112 appears safe and significantly reduces PGD₂ but not histamine or tryptase release in response to allergen challenge in subjects with AR.

Document Type: Research article

DOI: http://dx.doi.org/10.2500/aap.2006.27.2861

Publication date: 2006-05-01

More about this publication?

Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
Editorial Board
Information for Authors
Submit a Paper
Information for Advertisers
Reprint Requests
ingentaconnect is not responsible for the content or availability of external websites